A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

BACKGROUND: PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug. This phase 2 study evaluated PEP02 monotherapy as second-line treatment for pancreatic cancer. METHODS: Patients who had metastatic pancreatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, A H, Tempero, M A, Shan, Y-S, Su, W-C, Lin, Y-L, Dito, E, Ong, A, Wang, Y-W, Yeh, C G, Chen, L-T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749576/
https://www.ncbi.nlm.nih.gov/pubmed/23880820
http://dx.doi.org/10.1038/bjc.2013.408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749576/
https://www.ncbi.nlm.nih.gov/pubmed/23880820
http://dx.doi.org/10.1038/bjc.2013.408

Ejemplares similares